about
Recent advances of novel targeted therapy in non-small cell lung cancerSkin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysisInterventions for skin reactions associated with targeted anticancer treatmentsInterventions for skin reactions associated with targeted anticancer treatmentsMechanisms underlying skin disorders induced by EGFR inhibitorsRole of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patientsBiomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancerCutaneous adverse reactions specific to epidermal growth factor receptor inhibitorsMore than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsExpert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UKRosacea: The cytokine and chemokine networkPain related to cancer treatments and diagnostic procedures: a no man's land?Skin problems and EGFR-tyrosine kinase inhibitorAcneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New InsightsPanitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS StatusRASopathic skin eruptions during vemurafenib therapyNeutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptorCutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 PatientsRisk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFREpidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation.Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex.Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rashDermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.Randomized double-blind trial of prophylactic topical Evozac(®) Calming Skin Spray for gefitinib-associated acne-like eruption.Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancerPractical Management Recommendations for Anti-ErbB2 Therapy with Lapatinib.Tyrosine kinases in inflammatory dermatologic disease.Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs.Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.Targeted treatment of advanced and metastaticbreast cancer with lapatinib.Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II studyGefitinib-induced hair alterations.Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy.EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitorsTreatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers.Erlotinib-induced skin inflammation is IL-1 mediated in KC-Tie2 mice and human skin organ culture.Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
P2860
Q21092930-B75C2DB9-9716-4C69-8985-7F5EDFBE8C79Q21133732-1B6CBC99-4191-42C5-9ABD-E0494F8DF6BBQ24187823-6A0E8209-7614-4C46-82A9-7C993379D58EQ24235777-314A5E61-7469-4A10-B18C-F5D57753E46EQ26745689-F7C6847E-611F-426F-A7A9-9B97796AE229Q26750428-AB0DAB27-8F26-4539-A757-E495631CC1B1Q26774605-B72CDA47-8D5F-465E-9ABC-4C3458DD5ABEQ26781472-13E2906C-293D-406E-A3D5-A955AF4C122DQ26781662-DF1BB950-DA8D-4474-B7F5-711DAC32FB13Q26799390-82B4219E-CEBD-434D-B844-50B315392148Q27023344-B437786C-6E84-47A0-8029-7D4AB236C0C8Q27026749-CB0E031A-5E9D-4C4E-AD34-F56CDF25E824Q28069454-1EBC1986-CBF3-439E-A929-47CFE1EF1037Q28081446-8F0F738F-FA00-4B14-B480-9044B0D8A632Q28082816-F3FB7399-A606-4352-A6F0-04D7CCE13B9EQ28488013-7A18B25E-A2EC-4F70-ACAE-1C06B76E0556Q28728031-3A88877B-5B48-4843-98DE-C7856938555FQ29248067-1820BEC6-A8EF-499F-9F36-750E021969B6Q30248499-73D37927-1C64-4636-9EB1-7905850931BFQ30415389-9DEBC060-6F80-4D43-ADE0-C49870ACAD3FQ30515730-DF10572D-841B-499F-806F-E812121CB069Q33683529-704C0779-3DC3-459A-9238-59769E20332BQ33798783-E3553210-8C2A-4708-9DFC-EAA3F358AFCCQ33885559-B8427C45-9B54-460E-908E-3A93D124849DQ33895537-935047F5-F99B-40F5-B4F0-00D7CC87566CQ33983656-640617B6-72D6-437C-9786-6F10C99D384CQ34095753-B8DDA64D-F682-43C3-BD50-2E7F48A71CE2Q34166503-D80CD60A-F215-45EC-A9CC-FF15AC79702BQ34192836-CBF33321-BDBE-45E3-A3BD-962DDD204DF6Q34250187-28B9CDB8-2FE1-4D31-89F0-EE040C23237AQ34363419-AF8F5181-C36B-486E-BFE4-09FE2CAC1E3FQ34424047-D9E44CE8-D80E-4981-A662-78C555ED031EQ34524343-8E8FFAC0-B789-4B21-8066-E2A694A4E0F5Q34551761-EF8F2837-896A-46D9-BFD6-D8709708C25BQ34567451-7B0E2C50-0E8A-49F2-9E77-706ABF18309DQ34618994-6819BD23-9FBE-4E48-9F37-030DA26DF984Q35043780-1E2C9105-E4CA-491E-9C21-CCFF224D038DQ35059625-535D9263-1271-46A8-BAE4-986EA099A36CQ35071059-36E2F6A4-C181-40F5-A45D-96974D671091Q35083960-99EEAF9E-07C5-41CE-A42E-013F7F54D89D
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Mechanisms of cutaneous toxicities to EGFR inhibitors.
@ast
Mechanisms of cutaneous toxicities to EGFR inhibitors.
@en
Mechanisms of cutaneous toxicities to EGFR inhibitors.
@nl
type
label
Mechanisms of cutaneous toxicities to EGFR inhibitors.
@ast
Mechanisms of cutaneous toxicities to EGFR inhibitors.
@en
Mechanisms of cutaneous toxicities to EGFR inhibitors.
@nl
prefLabel
Mechanisms of cutaneous toxicities to EGFR inhibitors.
@ast
Mechanisms of cutaneous toxicities to EGFR inhibitors.
@en
Mechanisms of cutaneous toxicities to EGFR inhibitors.
@nl
P356
P1476
Mechanisms of cutaneous toxicities to EGFR inhibitors
@en
P2093
Mario E Lacouture
P2860
P2888
P304
P356
10.1038/NRC1970
P407
P577
2006-10-01T00:00:00Z
P6179
1022950805